BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6310359)

  • 1. Hexamethylmelamine in adenocarcinoma of the pancreas and liver.
    Oldham DS; Wampler GL
    Med Pediatr Oncol; 1983; 11(4):297-8. PubMed ID: 6310359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trials of hexamethylmelamine, dianhydrogalactitol, razoxane, and beta-2'-deoxythioguanosine as single agents against advanced measurable tumors of the pancreas. Gastrointestinal Tumor Study Group.
    Cancer Treat Rep; 1985 Jun; 69(6):713-6. PubMed ID: 3926311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma.
    Johnson BL; Fisher RI; Bender RA; DeVita VT; Chabner BA; Young RC
    Cancer; 1978 Nov; 42(5):2157-61. PubMed ID: 102417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hexamethylmelamine in advanced head and neck cancer. A phase II study.
    Gad-El-Mawla N; Macdonald JS; Khaled H
    Am J Clin Oncol; 1984 Jun; 7(3):205-8. PubMed ID: 6428214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hexamethylmelamine in mustard-resistant ovarian adenocarcinoma.
    Omura GA; Greco FA; Birch R
    Cancer Treat Rep; 1981; 65(5-6):530-1. PubMed ID: 6786741
    [No Abstract]   [Full Text] [Related]  

  • 6. cis-Dichlorodiammineplatinum(II) and hexamethylmelamine in the treatment of non-oat cell lung cancer: a pilot study of the Southeastern Cancer Study Group.
    Krauss S; Tornyos K; DeSimone P; Lowenbraun S; McKeown J; Solomon A; Sonoda T
    Cancer Treat Rep; 1979 Mar; 63(3):391-3. PubMed ID: 106964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of hexamethylmelamine for disseminated prostatic carcinoma.
    Drelichman A; Brownlee R; Al-Sarraf M
    Cancer Clin Trials; 1981; 4(3):309-12. PubMed ID: 6793256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of hexamethylmelamine in advanced ovarian carcinoma treatment.
    Weiss RB
    Gynecol Oncol; 1981 Oct; 12(2 Pt 1):141-9. PubMed ID: 6795094
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II trial of combination chemotherapy for pancreatic cancer with 5-fluorouracil, mitomycin C, and hexamethylmelamine.
    Bruckner HW; Storch JA; Brown JC; Goldberg J; Chamberlin K
    Oncology; 1983; 40(3):165-9. PubMed ID: 6405338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma.
    Kardinal CG; Luce JK
    Cancer Treat Rep; 1977 Dec; 61(9):1691-3. PubMed ID: 413624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hexamethylmelamine, vincristine, and methotrexate chemotherapy in advanced neoplasms.
    Longacre D; Donavan M; Paladine W; Cunningham T; Sponzo R
    Cancer Treat Rep; 1977 Aug; 61(5):919-22. PubMed ID: 408004
    [No Abstract]   [Full Text] [Related]  

  • 12. Hexamethylmelamine as a single agent in the treatment of small-cell carcinoma of the lung.
    Goldsweig HG; Edgerton F; Redden CS; Takita H; Garza JG; Bisel HF
    Am J Clin Oncol; 1982 Jun; 5(3):267-72. PubMed ID: 6282109
    [No Abstract]   [Full Text] [Related]  

  • 13. A phase III study in lung carcinoma comparing hexamethyl-melamine (NSC 13875) to dibromodulcitol (NSC 104800) 1,2.
    Wilson WL; Ryzin JV; Weiss AJ; Frelick RW; Moss SE
    Oncology; 1975; 31(5-6):293-309. PubMed ID: 174041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of prednisone to the effectiveness of hexamethylmelamine in multiple myeloma.
    Oken MM; Lenhard RE; Tsiatis AA; Glick JH; Silverstein MN
    Cancer Treat Rep; 1987 Sep; 71(9):807-11. PubMed ID: 3113729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phae II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy.
    Denefrio JM; Vogel CL
    Cancer Treat Rep; 1978 Jan; 62(1):173-5. PubMed ID: 414835
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapy of small cell carcinoma of the lung with hexamethylmelamine.
    Huang MN; Takita H; Catane H; Yee Chen T
    Oncology; 1978; 35(1):29-32. PubMed ID: 203884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.
    Bonomi PD; Mladineo J; Morrin B; Wilbanks G; Slayton RE
    Cancer Treat Rep; 1979 Jan; 63(1):137-8. PubMed ID: 105805
    [No Abstract]   [Full Text] [Related]  

  • 18. Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy.
    Stehman FB; Ehrlich CE; Callangan MF
    Gynecol Oncol; 1984 Feb; 17(2):189-95. PubMed ID: 6423460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hexamethylmelamine, bleomycin, and CCNU chemotherapy for patients with squamous cell carcinoma, large cell carcinoma, and adenocarcinoma of the lung unresponsive to cyclophosphamide, adriamycin, methotrexate, and procarbazine.
    Mintz U; Bitran JD; Cooksey JA; Desser RK; DeMeester TR; Golomb HM
    Cancer Treat Rep; 1978 Apr; 62(4):567-9. PubMed ID: 77725
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase I--II study of hexamethylmelamine plus dibromodulcitol in refractory carcinoma of the breast.
    Van Amburg AL; Presant CA; Vélez-García E; Klahr C
    Cancer Treat Rep; 1979 Jan; 63(1):141-2. PubMed ID: 105806
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.